 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 February 1997 | Volume 126 Issue 3 | Pages 177-183
Background: The increasing costs of managing asthma are due in part to the introduction of new medications, such as leukotriene receptor antagonists. These antagonists interfere with the action of leukotrienes, which are implicated in bronchoconstriction and the formation of airway edema in patients with asthma. Leukotriene receptor antagonists must be shown to be clinically and economically effective for their clinical use to be justified.
Objective: To assess the clinical and economic effectiveness of zafirlukast, a leukotriene receptor antagonist, in patients with mild-to-moderate asthma who might benefit from regular anti-inflammatory therapy.
Design: Randomized, double-blind, multicenter, placebo-controlled trial.
Setting: 28 outpatient clinics.
Patients: 146 patients with mild-to-moderate asthma who were 12 years of age or older, had not smoked cigarettes in the previous 6 months, had a smoking history of less than 10 pack-years, had an FEV1 at least 55% of the predicted value with no upper limit, had demonstrated bronchial hyperresponsiveness, and were symptomatic during the 7-day run-in period. All patients were seen every 2 to 3 weeks for 13 weeks.
Intervention: 103 patients received zafirlukast (20 mg twice daily), and 43 patients received placebo (twice daily). All patients received inhaled ß-agonists as needed.
Measurements: Data were obtained from medical examinations, patient questionnaires, and daily diaries. The clinical effectiveness outcomes were days per month without asthma symptoms, limitation of activity, use of ß-agonists, sleep disturbance, and episodes of asthma (the latter was a composite measure made up of the first four outcomes plus the occurrence of adverse events). The economic effectiveness outcomes were frequency and type of unscheduled health care contacts, use of ß-agonist inhalers, consumption of nonasthma medications, and days of absence from work or school.
Results: The zafirlukast group had 89% more days without symptoms (adjusted rates, 7.0 compared with 3.7 days per month; P = 0.03), 89% more days without use of ß-agonists (adjusted rates, 11.3 compared with 6.0 days per month; P = 0.001), and 98% more days without episodes of asthma (adjusted rates, 10.1 compared with 5.1 days per month; P = 0.003). They also had 55% (95% CI, 19% to 74%) fewer health care contacts (18.5 compared with 40.7 per 100 per month; P = 0.007) and 55% (CI, 3% to 79%) fewer days of absence from work or school (15.6 compared with 35.0 per 100 per month; P = 0.04). They used 17% fewer canisters of inhaled ß-agonists (P = 0.17) and 19% less nonasthma medication (P > 0.2).
Conclusions: A daily regimen of zafirlukast added to as-needed inhaled ß-agonists is more effective than ß-agonists alone in treating mild-to-moderate asthma. The clinical and economic effectiveness of zafirlukast, a potential alternative to inhaled corticosteroids, provides further impetus to use regular "preventive" therapy in patients with mild-to-moderate asthma.
Author and Article Information
From the Royal Victoria Hospital, Montreal General Hospital, and McGill University, Montreal, Quebec, Canada; and the Universidad Javeriana, Bogota, Colombia.
ARTICLE
Effectiveness of the Leukotriene Receptor Antagonist Zafirlukast for Mild-to-Moderate Asthma
A Randomized, Double-Blind, Placebo-Controlled Trial
Acknowledgments: The authors thank Dr. Vincent Ciuryla and Mr. Kaylor Kowash of Zeneca Pharmaceuticals (Wilmington, Delaware) for their participation in the study design; Dr. Santiago Echeverri of Universidad Javeriana (Bogota, Colombia) for his assistance in data analysis; and Drs. Jean-Francois Boivin, Steven Grover, and Pierre Tousignant of McGill University (Montreal, Quebec, Canada) for their advice.
Grant Support: In part by a grant from Zeneca Pharmaceuticals, Canada, Ltd., and by a doctoral fellowship from Boehringer-Ingelheim Pharmaceuticals, Canada (Dr. Dennis). Dr. Suissa is a research scholar of the Fonds de la Recherche en Sante du Quebec, and the McGill Pharmacoepidemiology Research Unit is funded by the Fonds de la Recherche en Sante du Quebec.
Requests for Reprints: Samy Suissa, PhD, Division of Clinical Epidemiology, Royal Victoria Hospital, 687 Pine Avenue West, Ross 4.29, Montreal, Quebec H3A 1A1, Canada.
Current Author Addresses: Dr. Suissa and Ms. Sheehy: Division of Clinical Epidemiology, Royal Victoria Hospital, 687 Pine Avenue West, Ross 4.29, Montreal, Quebec H3A 1A1, Canada.
This article has been cited by other articles:
|
|
 |
|
  M. Peters-Golden and W. R. Henderson Jr. Leukotrienes N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854. [Full Text] [PDF]
|
|
|
|
 |
|
 Pharmacotherapy -- first-line maintenance therapy Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S28 - S32. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Busse and M. Kraft Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy Chest, April 1, 2005; 127(4): 1312 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J White, A Vanthuyne, P M Wood, and J G Ayres Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study Sex. Transm. Inf., June 1, 2004; 80(3): 219 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Yang, A. Haczku, H. Chen, V. Martin, H. Galczenski, Y. Tomer, C. R. Van Beisen, J. F. Evans, R. A. Panettieri, and C. D. Funk Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4 Am J Physiol Lung Cell Mol Physiol, May 1, 2004; 286(5): L992 - L1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Snyder, P. D. Blanc, P. P. Katz, E. H. Yelin, and M. D. Eisner Leukotriene Modifier Use and Asthma Severity: How Is a New Medication Being Used by Adults With Asthma? Arch Intern Med, March 22, 2004; 164(6): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Mellor, N. Frank, D. Soler, M. R. Hodge, J. M. Lora, K. F. Austen, and J. A. Boyce Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R PNAS, September 30, 2003; 100(20): 11589 - 11593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Yopp, G. J. Randolph, and J. S. Bromberg Leukotrienes, Sphingolipids, and Leukocyte Trafficking J. Immunol., July 1, 2003; 171(1): 5 - 10. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa and P. Ernst Use of anti-inflammatory therapy and asthma mortality in Japan Eur. Respir. J., January 1, 2003; 21(1): 101 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Miller and A. F. Shorr Unnecessary Use of Placebo Controls: The Case of Asthma Clinical Trials Arch Intern Med, August 12, 2002; 162(15): 1673 - 1677. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ogasawara, S. Ishii, T. Yokomizo, T. Kakinuma, M. Komine, K. Tamaki, T. Shimizu, and T. Izumi Characterization of Mouse Cysteinyl Leukotriene Receptors mCysLT1 and mCysLT2. DIFFERENTIAL PHARMACOLOGICAL PROPERTIES AND TISSUE DISTRIBUTION J. Biol. Chem., May 17, 2002; 277(21): 18763 - 18768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cates Extracts from ""Clinical Evidence"": Chronic asthma BMJ, October 27, 2001; 323(7319): 976 - 979. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Mellor, A. Maekawa, K. F. Austen, and J. A. Boyce Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells PNAS, July 3, 2001; 98(14): 7964 - 7969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Bourdet and D. Williams Management Considerations for Chronic Asthma Journal of Pharmacy Practice, April 1, 2001; 14(2): 108 - 125. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Eccles, N. Rousseau, B. Higgins, and L. Thomas Evidence-based guideline on the primary care management of asthma Fam. Pract., April 1, 2001; 18(2): 223 - 229. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. MOY, E. ISRAEL, S. T. WEISS, E. F. JUNIPER, L. DUBÉ, J. M. DRAZEN, and the NHLBI Asthma Clinical Rese Clinical Predictors of Health-related Quality of Life Depend on Asthma Severity Am. J. Respir. Crit. Care Med., March 15, 2001; 163(4): 924 - 929. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Bisgaard Leukotriene Modifiers in Pediatric Asthma Management Pediatrics, February 1, 2001; 107(2): 381 - 390. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. FIGUEROA, R. M. BREYER, S. K. DEFOE, S. KARGMAN, B. L. DAUGHERTY, K. WALDBURGER, Q. LIU, M. CLEMENTS, Z. ZENG, G. P. O'NEILL, et al. Expression of the Cysteinyl Leukotriene 1 Receptor in Normal Human Lung and Peripheral Blood Leukocytes Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 226 - 233. [Abstract] [Full Text]
|
|
|
|
 |
|
 O J Dempsey Leukotriene receptor antagonist therapy Postgrad. Med. J., December 1, 2000; 76(902): 767 - 773. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. G. Goransson and R. Omdal A severe systemic inflammatory reaction following therapy with montelukast (Singulair(R)) Nephrol. Dial. Transplant., July 1, 2000; 15(7): 1054 - 1055. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wechsler, D. Finn, D. Gunawardena, R. Westlake, A. Barker, S. P. Haranath, R. A. Pauwels, J. C. Kips, and J. M. Drazen Churg-Strauss Syndrome in Patients Receiving Montelukast as Treatment for Asthma Chest, March 1, 2000; 117(3): 708 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Casale Immunobiology of Asthma and Rhinitis . Pathogenic Factors and Therapeutic Options Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1778 - 1787. [Full Text]
|
|
|
|
|
|
Leukotriene-receptor antagonists and related compounds Can. Med. Assoc. J., November 1, 1999; 161(90111): s31 - 34. [Full Text]
|
|
|
|
 |
|
 S. E. Wenzel Antileukotriene Drugs in the Management of Asthma JAMA, December 23, 1998; 280(24): 2068 - 2069. [Full Text] [PDF]
|
|
|
|
|
|
J. M. DRAZEN and E. ISRAEL Should Antileukotriene Therapies Be Used Instead of Inhaled Corticosteroids in Asthma? . Yes Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1697 - 1698. [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Montelukast and {blacktriangledown}zafirlukast in asthma DTB, September 1, 1998; 36(9): 65 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wechsler, E. Garpestad, S. R. Flier, O. Kocher, D. A. Weiland, A. J. Polito, M. M. Klinek, T. D. Bigby, G. A. Wong, R. A. Helmers, et al. Pulmonary Infiltrates, Eosinophilia, and Cardiomyopathy Following Corticosteroid Withdrawal in Patients With Asthma Receiving Zafirlukast JAMA, February 11, 1998; 279(6): 455 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. DRAZEN Clinical Pharmacology of Leukotriene Receptor Antagonists and 5-Lipoxygenase Inhibitors Am. J. Respir. Crit. Care Med., June 1, 1997; 157(6): 233S - 237. [Abstract] [Full Text]
|
|
|
|
|
|
W. J. CALHOUN Summary of Clinical Trials with Zafirlukast Am. J. Respir. Crit. Care Med., June 1, 1997; 157(6): 238S - 246. [Abstract] [Full Text]
|
|
|
|
 |
|
 ZAFIRLUKAST FOR MILD-TO-MODERATE ASTHMA Journal Watch (General), February 18, 1997; 1997(218): 3 - 3. [Full Text]
|
|
|
|
|
|
C. E. Heise, B. F. O'Dowd, D. J. Figueroa, N. Sawyer, T. Nguyen, D.-S. Im, R. Stocco, J. N. Bellefeuille, M. Abramovitz, R. Cheng, et al. Characterization of the Human Cysteinyl Leukotriene 2 Receptor J. Biol. Chem., September 22, 2000; 275(39): 30531 - 30536. [Abstract] [Full Text] [PDF]
|
|
Article
